NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $12.02 -0.15 (-1.19%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zymeworks Stock (NYSE:ZYME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zymeworks alerts:Sign Up Key Stats Today's Range$12.40▼$12.4050-Day Range$11.64▼$14.4852-Week Range$9.03▼$17.70Volume180 shsAverage Volume531,405 shsMarket Capitalization$837.24 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company Overview Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. Read More Zymeworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreZYME MarketRank™: Zymeworks scored higher than 54% of companies evaluated by MarketBeat, and ranked 376th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 3 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.24% of the float of Zymeworks has been sold short.Short Interest Ratio / Days to CoverZymeworks has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Zymeworks has recently decreased by 29.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.24% of the float of Zymeworks has been sold short.Short Interest Ratio / Days to CoverZymeworks has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Zymeworks has recently decreased by 29.94%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Zymeworks this week, compared to 6 articles on an average week.Search Interest1 people have searched for ZYME on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have bought more of their company's stock than they have sold. Specifically, they have bought $635,534.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.92% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Stock News HeadlinesZymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7 at 4:18 PM | globenewswire.comBispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...July 30, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 8 at 2:00 AM | Porter & Company (Ad)Zymeworks Inc.: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug ConjugateJuly 28, 2025 | finanznachrichten.deZymeworks Shares Climb After FDA Clears Investigational New Drug ApplicationJuly 28, 2025 | marketwatch.comZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug ConjugateJuly 28, 2025 | globenewswire.comZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025July 17, 2025 | financialpost.comFSee More Headlines ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $14.64 at the beginning of the year. Since then, ZYME shares have decreased by 17.9% and is now trading at $12.0150. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) issued its earnings results on Thursday, August, 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.55. The firm's revenue for the quarter was up 153.2% compared to the same quarter last year. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Top institutional investors of Zymeworks include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.93%), Assenagon Asset Management S.A. (0.71%), Platinum Investment Management Ltd. (0.34%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.08%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Paul Andrew Moore, Neil Josephson, Jeffrey T L Smith and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CIK1937653 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees460Year FoundedN/APrice Target and Rating Average Price Target for Zymeworks$21.00 High Price Target$30.00 Low Price Target$13.00 Potential Upside/Downside+72.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.67 million Net Margins-182.75% Pretax Margin-189.75% Return on Equity-23.00% Return on Assets-18.04% Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio4.10 Sales & Book Value Annual Sales$93.38 million Price / Sales9.07 Cash FlowN/A Price / Cash FlowN/A Book Value$6.63 per share Price / Book1.83Miscellaneous Outstanding Shares69,683,000Free Float67,556,000Market Cap$847.35 million OptionableOptionable Beta1.26 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:ZYME) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.